Verastem Oncology VSTM
Verastem Oncology (Nasdaq: VSTM) is an oncology drug developer. Its lead program, VS-7375, is in Phase 3 for KRAS G12D-mutated solid tumors (pancreatic, lung, colorectal cancers). Its next catalyst on record is VS-7375 combinations with EGFR & chemotherapy: VS-7375 combinations in mCRC expect to open by end of 2026. (Q4 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: VS-7375 combinations with EGFR & chemotherapy — VS-7375 combinations in mCRC expect to open by end of 2026. (Q4 2026). 26 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| AVMAPKI FAKZYNJA CO-PACK (avutometinib + defactinib) | KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) | small molecule | Approved |
| VS-7375 - TARGET-D 301 | First-line metastatic pancreatic ductal adenocarcinoma (KRAS G12D) | small molecule | Phase 3 |
| VS-7375 - TARGET-D 302 | First-line advanced NSCLC (KRAS G12D) | small molecule | Phase 3 |
| VS-7375 - TARGET-D 303 | First-line metastatic colorectal cancer (KRAS G12D) | small molecule | Phase 3 |
| Avutometinib + defactinib - RAMP 301 | Recurrent LGSOC with or without KRAS mutation | small molecule | Phase 3 |
| VS-7375 - TARGET-D 201 | Second-line PDAC (KRAS G12D) | small molecule | Phase 2 |
| VS-7375 - TARGET-D 202 | 2L/3L NSCLC (KRAS G12D) | small molecule | Phase 2 |
| VS-7375 - TARGET-D 203 | 2L+ metastatic CRC (KRAS G12D) | small molecule | Phase 2 |
| VS-7375 - TARGET-D 101 | Advanced KRAS G12D solid tumors | small molecule | Phase 2 |
Recent results and decisions
- Oct 14, 2026positive VS-7375 600 mg monotherapy in 2L+ KRAS G12D NSCLC showed 43% confirmed ORR (10/23), 72% 6-month landmark PFS, 17/23 on treatment (cutoff Oct 7, 2026).
VS - 7375 Demonstrates Confirmed Responses at 600 mg in 2L+ NSCLC 43% c ORR (10/23) 2L+ NSCLC, including prior taxane treated
Filing - Oct 14, 2026positive VS-7375 600 mg with first-line SoC triplet in KRAS G12D NSCLC showed 75% ORR (6/8), 6/8 remain on treatment.
75% ORR* (6/8) in 1L NSCLC combined with SoC mITT = 8 patients
Filing - Oct 14, 2026met VS-7375 achieved 50% confirmed ORR (4/8) in second-line KRAS G12D mPDAC and 41% confirmed ORR (9/22) in 2L+ setting, including two complete responses.
VS-7375 900 mg QD monotherapy achieved a 41% confirmed ORR in the broader 2L+ pancreatic ductal adenocarcinoma (PDAC) patient population and a 36% confirmed ORR in 3-4L.
Filing
16 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 oncology companies
- Astrazeneca PLC AZN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Revolution Medicines, Inc. RVMD
- Genmab A/S GMAB
- BioNTech SE BNTX
- Guardant Health, Inc. GH
- Exelixis, Inc. EXEL
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.